PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25026N0359Pylarify radiopharmaceutical cleveland VAMC — Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals Inc holds $95.0M across 149 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79725D0093. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: SBA. Recompete timing centers on the Feb 28, 2027 PoP end — agencies typically plan 12–18 months ahead.

250-Network Contract Office 10 (36C250)

Awarding office

Progenics Pharmaceuticals Inc

Recipient

Feb 28, 2027

PoP end

$2M

Obligated

$2M

Potential

325412

NAICS

6505

PSC

SBA

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Progenics Pharmaceuticals Inc — $90

Contract facts

SBA

Contract number36C25026N0359

Also listed as36C250-26-N-0359

Also listed as36F79725D0093-36C25026N0359

Agency250-Network Contract Office 10 (36C250)

Awarding office250-Network Contract Office 10 (36C250)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentProgenics Pharmaceuticals Inc

CAGE34KE9

UEIYLYKVRPCTCR3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79725D0093

Place of performanceBEDFORD MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startMar 1, 2026

PoP end (current)Feb 28, 2027

Obligated$2M

Current value$2M

Potential value$2M

PYLARIFY RADIOPHARMACEUTICAL CLEVELAND VAMC 541A60266 is a federal SBA award for 250-Network Contract Office 10 (36C250) held by Progenics Pharmaceuticals Inc. Estimated value $2M ($2M obligated). Current period of performance ends Feb 28, 2027. Last award drew 1 bidder. Place of performance: BEDFORD MA.

PYLARIFY RADIOPHARMACEUTICAL CLEVELAND VAMC 541A60266

Recompete timing

Public

● Expiring in 191 days

Current PoP ends Feb 28, 2027 (191 days remaining). Agencies typically plan 12–18 months ahead — at 6.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Progenics Pharmaceuticals Inc — $95.0M obligated across 149 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($95.0M) · all agencies

Department of Veterans Affairs (VA)$93.8M · 99%Department of Health and Human Services (HHS)$1.1M · 1%Department of Defense (DOD)$105K · 0%

Open full company profile →

Related awards

Same parent · incumbent

36C24625N1142

PYLARIFY F-18 INJECTIONS (336)

$1.2M

Aug 31, 2026

75N90025F00021

PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO.:1108959 [25-004297]

$611K

Sep 25, 2026

36C26126N0023

480 F18 PYLARIFY DOSES POP 1/1/2025 - 12/31/2025

$1.7M

Sep 26, 2026

75N90025F00003

PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO. [POTS 25-000073]

$2.1M

Sep 29, 2026

36C26122N0385

PYLARIFY (PIFLUFOLASTAT F18) NDC: 71258-0022-01

$4.5M

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C25026N0359?

36C25026N0359 (Pylarify radiopharmaceutical cleveland VAMC) is a 250-Network Contract Office 10 (36C250) award with a potential value of $2M, currently held by Progenics Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C250-26-N-0359?

36C250-26-N-0359 is the dashed form of PIID 36C25026N0359 (Pylarify radiopharmaceutical cleveland VAMC), held by Progenics Pharmaceuticals Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25026N0359?

250-Network Contract Office 10 (36C250) awarded 36C25026N0359 to Progenics Pharmaceuticals Inc (potential $2M).

Who is the incumbent on 36C25026N0359?

Progenics Pharmaceuticals Inc is the incumbent with $95.0M across 149 related awards in SCOUT’s public footprint. The current period of performance ends Feb 28, 2027.

When does Progenics Pharmaceuticals Inc’s 36C25026N0359 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 28, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Feb 28, 2026